Court proceedings initiated for immediate market approval of Brixadi™ in the US
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product.
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product. Buvidal is approved for the treatment of opioid dependence in the EU and Australia.
Read more at Camurus’ website: https://www.camurus.com/pressreleases/
Latest news
2024-04-16
Research donation from Sandberg Development for increased knowledge about water
In April 2024, Sandberg Development donated 100 million Swedish kronor, distributed over a 10-year period, to Malmö…